ABNOM
☆ AI Dermatology — Free Service
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
relevance score : -100.0%
ReferencesLazè Q‑switched Nd:YAG se yon aparèy ki efikas pou trete nevus, Ota, ak lòt kondisyon ki sanble. Nou te fè yon etid pou evalye kijan yon lazè high‑fluence 1064 nm Q‑switched Nd:YAG fonksyone sou tach Mongolyen ki pa nòmal, san li pa lakòz eklere po a. Nou te etidye 61 pasyan ki te gen tach sa yo, epi nou te egzamine yon total 70 blesi. Mwatye nan blesi yo te trete ak lazè a, pandan lòt yo te kite san tretman pou konparezon. Nou te evalye rezilta yo lè l sèvi avèk yon echèl ak yon aparèy ki rele Mexameter® pou mezire nivo melanin. Pasyan yo te swiv pou yon mwayèn de 14 mwa nan gwoup tretman an ak 18 mwa nan gwoup obsèvasyon an. Nan fen etid la, nou te jwenn yon diferans ki enpòtan ant nòt echèl yo ak nivo melanin pou gwoup ki te trete ak gwoup ki pa t trete, kote gwoup ki te resevwa lazè a te montre pi bon rezilta. Lazè high‑fluence Q‑switched Nd:YAG, san li pa lakòz eklere po, pwouve li efikas ak san danje pou trete tach Mongolyen ki etranj.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Nou te etidye efikasite ak sekirite lè w sèvi ak yon tretman lazè espesifik pou ABNOM, epi nou te gade ki faktè ki ka afekte kouman li fonksyone. Nou te obsève 110 pasyan ki te gen ABNOM epi ki te resevwa ant de ak nèf tretman lazè. Nou te jwenn ke tretman an te travay pi byen lè li te dire pi lontan, men li pa t osi efikas nan pasyan ki pi gran yo. Li te travay pi byen tou nan pasyan ki gen po ki pi lejè (tip III) ak pi piti zòn ki afekte (mwens pase 10 cm²). Prezans melasma ansanm ak ABNOM te fè tretman an mwens efikas. Koulè oswa kantite zòn ki afekte yo pa t sanble fè yon diferans. Apeprè 10 % pasyan yo te devlope tach ki pi fonse apre tretman an. Tretman miltip bonè te bay bon rezilta. Pasyan ki pi gran, ki gen po ki pi fonse ak tach ki pi fonse, gen plis chans pou yo devlope tach ki pi fonse apre tretman an. Pou pasyan ki gen ABNOM ak melasma, li pi bon pou itilize yon lazè ki pi ba enèji pou evite agrave melasma a.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Tretman
Ajan blanchiman raman ede. Kontrèman ak melasma, ABNOM ka amelyore ak tretman lazè epi retire san repete. Tretman lazè ka fèt 10 a 20 fwa pou trete ABNOM.
#QS1064 laser